Background-Downregulation of ␤-adrenergic receptors (␤ARs) under conditions of heart failure requires receptor targeting of phosphoinositide 3-kinase (PI3K)-␥ and redistribution of ␤ARs into endosomal compartments. Because support with a left ventricular assist device (LVAD) results in significant improvement of cardiac function in humans, we investigated the effects of mechanical unloading on regulation of PI3K␥ activity and intracellular distribution of ␤ARs. Additionally, we tested whether displacement of PI3K␥ from activated ␤ARs would restore agonist responsiveness in failing human cardiomyocytes. Methods and Results-To test the role of PI3K on ␤AR endocytosis in failing human hearts, we assayed for PI3K activity in human left ventricular samples before and after mechanical unloading (LVAD). Before LVAD, failing human hearts displayed a marked increase in ␤AR kinase 1 (␤ARK1)-associated PI3K activity that was attributed exclusively to enhanced activity of the PI3K␥ isoform. Increased ␤ARK1-coupled PI3K activity in the failing hearts was associated with downregulation of ␤ARs from the plasma membrane and enhanced sequestration into early and late endosomes compared with unmatched nonfailing controls. Importantly, LVAD support reversed PI3K␥ activation, normalized the levels of agonist-responsive ␤ARs at the plasma membrane, and depleted the ␤ARs from the endosomal compartments without changing the total number of receptors (sum of plasma membrane and early and late endosome receptors). To test whether the competitive displacement of PI3K from the ␤AR complex restored receptor responsiveness, we overexpressed the phosphoinositide kinase domain of PI3K (which disrupts ␤ARK1/PI3K interaction) in primary cultures of failing human cardiomyocytes. Adenoviral-mediated phosphoinositide kinase overexpression significantly increased basal contractility and rapidly reconstituted responsiveness to ␤-agonist. Conclusions-These results suggest a novel paradigm in which human ␤ARs undergo a process of intracellular sequestration that is dynamically reversed after LVAD support. Importantly, mechanical unloading leads to complete reversal in PI3K␥ and ␤ARK1-associated PI3K activation. Furthermore, displacement of active PI3K from ␤ARK1 restores ␤AR responsiveness in failing myocytes.
H eart failure is the common clinical syndrome that results from virtually all forms of cardiac disease and is consistently characterized by extensive abnormalities in the ␤-adrenergic receptor (␤AR) system. 1, 2 A vast body of evidence indicates that ␤AR dysfunction is an early event in the transition of the overloaded heart toward failure, triggered by a combination of excessive neurohumoral stimulation and mechanical stress. 3 Indeed, either mechanical unloading of the left ventricle through the use of left ventricular assist devices (LVADs) or ␤-blocker therapy consistently ameliorates left ventricular dysfunction and restores ␤AR signaling in human heart failure. 4 -8 Clinical Perspective p 2579 ␤AR desensitization and downregulation are the classic receptor abnormalities associated with human heart failure. Desensitization of ␤ARs is initiated by phosphorylation of the receptor by ␤AR kinase 1 (␤ARK1). 9,10 ␤-Arrestin binds to the phosphorylated ␤AR sterically, which hinders further G-protein coupling (desensitization) and commences the process of receptor internalization. 10 Internalized ␤ARs are trafficked through specialized endosomal compartments based on the fate of the receptor. Receptors trafficking through early endosomes are thought to undergo dephosphor-ylation before being recycled back to the plasma membrane. 11 Receptors trafficking through late endosomes are targeted for the lysosomal degradation pathway. 11 According to the current paradigm, a combination of increased rates of ␤ 1 AR lysosomal degradation and reduced receptor transcript determines selective ␤ 1 AR downregulation at the plasma membrane under conditions of heart failure. 12, 13 However, the durations for which the internalized receptors reside in each of the endosomal compartments are currently unknown. Moreover, it is not known whether the path toward degradation can be blocked or even reversed. Indeed, accumulating evidence now suggests that the process of internalization itself may be pathological, because the internalization of receptors can activate detrimental signaling pathways directly. 14 Therefore, strategies that might alter receptor endocytosis may exert a beneficial effect in heart failure.
The intracellular route of internalized ␤ARs in end-stage human heart failure and the molecules involved in their trafficking toward lysosomal degradation are not clearly known. Our previous studies have shown that efficient ␤AR internalization requires the recruitment of phosphoinositide 3-kinase (PI3K) to agonist-stimulated ␤ARs. 15, 16 The recruitment of PI3K to the ␤AR is brought about by ␤ARK1, which associates with PI3K to form a cytosolic complex through the phosphoinositide kinase (PIK) domain of PI3K. 15, 16 Indeed, cardiac-specific overexpression of the PIK domain competitively displaces all of the endogenous isoforms of PI3K from ␤ARK1, which results in reduced ␤AR-localized PI3K activity. 17 Importantly, targeted PI3K inhibition prevents ␤AR sequestration into endosomal compartments despite chronic agonist stimulation and reverses ␤AR abnormalities in a large-animal model of heart failure. 17 Because very little is known about ␤AR trafficking in the heart, we hypothesized that the dynamic sequestration of ␤ARs into endosomal compartments may represent an important mechanism to regulate adrenergic responsiveness in the failing human heart. Furthermore, we tested the hypothesis that ␤AR-targeted PI3K activity plays a pivotal role in receptor sequestration using a gene transfer approach. This approach allowed us to determine whether competitive displacement of PI3K from the receptor complex would reconstitute ␤AR responsiveness to ␤-agonist stimulation in failing human cardiomyocytes.
Methods

Patient Characteristics
Paired samples of left ventricular tissue were obtained from 18 patients at a single institution at the time of LVAD implantation and at subsequent orthotopic heart transplantation. The indication for LVAD implantation in all patients was end-stage heart failure with deterioration of cardiac function despite maximal medical therapy (New York Heart Association class IV). Patients were enrolled between May 2000 and April 2006. After a period of LVAD support (Table) , these patients had their LVAD explanted and a heart transplant performed. Nonfailing control myocardium was obtained from 10 unmatched organ donors whose hearts were not suitable for transplantation in spite of normal ventricular structure and function. All procedures for tissue procurement were performed in compliance with institutional guidelines for human research and an approved institutional review board protocol at Duke University Medical Center and The Cleveland Clinic Foundation.
Myocardial Tissue
A transmural apical core of the left ventricle was excised during LVAD implantation. The specimen was examined, and any visible M  W  IDC  26  HeartMate XVE  AM, DOP, MIL, NE  AI   2  50  M  W  ISC  39  HeartMate XVE  AI, AM, CAR, MIL, NTG, ST  N/A   3  61  F  W  ISC  85  Thoratec LVAD  AI, DOB, DOP, ST  N/A   4  58  M  W  ISC  52  Thoratec BIVAD  DOB, ST  N/A   5  54  M  W  ISC  33  HeartMate XVE  AI, CAR, DIG, LID, MIL, ST  AI   6  56  M  W  ISC  21  HeartMate XVE  AI, AM, CAR, DIG, ISO, MIL, ST  AM   7  61  M  W  ISC  190  HeartMate XVE  AI, AM, CAR, DIG, MIL, NTG, scar tissue was excised and discarded. The remaining myocardium was snap-frozen in liquid nitrogen and stored at Ϫ80°C. A second sample of myocardium was taken from the left ventricular free wall at the time of cardiac transplantation and stored at Ϫ80°C. All samples were paired from LVAD implantation to explantation (nϭ18). Nonfailing left ventricular tissue was obtained in a similar fashion from organ donor hearts deemed unsuitable for transplantation but demonstrated no evidence of functional or structural heart disease.
Purification of Plasma Membrane, Early Endosomes, and Late Endosomes
To separate the plasma membrane and cytosolic fractions from the left ventricles, cardiac samples were homogenized in ice-cold lysis buffer containing 5 mmol/L Tris-Cl pH 7.5, 5 mmol/L EDTA, 1 mmol/L PMSF, and 2 g/mL leupeptin and aprotinin. Intact cell debris and nuclei were removed by centrifugation at 1000g for 5 minutes. The collected supernatant was subjected to centrifugation at 37 000g for 20 minutes. The crude supernatant cytosolic fraction was transferred to a new tube, and the pellet of cardiac membranes was resuspended in 75 mmol/L Tris-HCl pH 7.5, 2 mmol/L EDTA, 12.5 mmol/L MgCl 2 . Early and late endosomal fractions were recovered after ultracentrifugation of the crude cytosolic fraction for 1 hour at 300 000g and 200 000g, respectively. The pellets corresponding to early and late endosomes were resuspended in 75 mmol/L Tris-Cl pH 7.5, 2 mmol/L EDTA, 12.5 mmol/L MgCl 2 , and fractions were immunoblotted for the early and late endosomal markers Rab5 and Lampl, respectively. 17 
␤AR Radioligand Binding and Adenylyl Cyclase Activity
Receptor binding with 20 g of protein from the plasma membrane and early/late endosomal fractions was performed as described previously 17 with ␤AR ligand [ 125 I]-cyanopindolol (250 pmol/L). All assays were performed in triplicate, and receptor density (in femtomoles) was normalized to milligrams of membrane protein. Adenylyl cyclase assays were performed as described previously 17 with 20 g of the membrane fraction under basal conditions and after stimulation with isoproterenol (10 Ϫ4 mol/L). Generated cAMP was quantified with a liquid scintillation counter (MINAXI-4000, Packard Instrument Co/PerkinElmer, Waltham, Mass).
PI3K Activity
PI3K assays were performed by immunoprecipitation of the PI3K ␣and ␥-isoforms from the cytosolic fraction, as described previously. 15 ␤ARK1-associated PI3K activity was measured after immunoprecipitation of 400 g of proteins from the membrane fraction with a polyclonal antibody directed against ␤ARK1 (Santa Cruz Biotechnology, Santa Cruz, Calif). After the lipid kinase assay, lipids were extracted with chloroform/methanol (ratio of 1:1). The organic phase was spotted on thin-layer chromatography plates and resolved chromatographically with 2N glacial acetic acid/1-propanol (35:65). Dried plates were exposed for autoradiography. These signals were further quantified with Bio-Rad Fluoro-S MultiImager software (Bio-Rad, Hercules, Calif).
Primary Culture of Failing Human Cardiac Myocytes and Cell Contractility Studies
Cell contractility studies were performed on human cardiac myocytes isolated as described previously. 18 The myocytes were infected with AdEV (empty virus) or AdPIK (which encoded the PIK domain of PI3K) viruses at a multiplicity of infection (MOI) of 100, as described previously. 18 Uninfected cells from the same preparations were used as controls. Thirty-six to 48 hours after infection, single-cell contractions were measured in rod-shaped cells by video edge detection (Crescent Electronics, Sandy, Utah). The recordings were made during electric field stimulation in basal conditions and after administration of isoproterenol 1 mol/L, as described previously. 18
Confocal Microscopy in Fixed Cells
Confocal microscopy was performed as described previously. 17 Briefly, failing human cardiac myocytes were plated onto glassbottomed dishes and infected with an MOI of 100 for adenoviruses encoding either green fluorescent protein (AdGFP) or FLAG-PIK (AdPIK). Cells infected with AdEV were used as control cells for visualization. Cells were fixed in 8% paraformaldehyde and made permeable with a solution that contained 0.5% Triton X-100 in PBS. FLAG-PIK expression was visualized by incubation of cells with anti-FLAG monoclonal antibody (1:500, Sigma, St. Louis, Mo) followed by goat anti-mouse IgG conjugated with Texas Red (1:500, Molecular Probes, Carlsbad, Calif). Samples were all visualized with single sequential line excitation filters at 488 and 568 nm and emission filters set at 505 to 550 nm for GFP detection and 585 for Texas Red detection.
RNA Isolation and Northern Blotting
RNA was isolated from left ventricles with the RNA-Bee-RNA isolation reagent (Tel-Test, Friendswood, Tex). Briefly, samples were homogenized in 1.0 mL of RNA-Bee reagent with a polytron homogenizer. Chloroform (0.2 mL) was added to the homogenate and mixed vigorously for 15 to 30 seconds. The samples were incubated on ice for 5 minutes and centrifuged at 12 000g for 15 minutes at 4°C. The aqueous phase was transferred to a new tube, and 0.5 mL isopropanol was added. The tubes were incubated for 10 minutes at room temperature. RNA was precipitated by centrifugation at 12 000g for 5 minutes at 4°C. The RNA pellet was washed with 75% ethanol, air-dried, and resuspended in RNase-free water. Ten micrograms of RNA was size-fractionated by denaturing formaldehyde gel electrophoresis, transferred to nylon membrane by capillary action, and cross-linked with ultraviolet light. The membrane was stained with 0.5% methylene blue to visualize the transferred RNA onto the nylon membrane and also to check for equal loading across lanes. The membrane was destained with diethyl pyrocarbonate-treated sterile water. After destaining, the membrane was hybridized with a human ␤ 1 AR [ 32 P]-labeled cDNA probe. The nylon membrane was stripped and reprobed with ␤ 2 AR [ 32 P]-labeled cDNA probe. After hybridization, filters were washed under stringent conditions, and transcripts were detected by autoradiography.
Statistical Analysis
Data are expressed as meanϮSEM repeated-measures ANOVA. Changes in the same human samples before and after LVAD were evaluated by repeated-measures ANOVA. One-way ANOVA was used when single values were compared, and 2-way ANOVA with Bonferroni correction was used when multiple comparisons were performed. For all analyses, PϽ0.05 was considered significant, and in case of multiple comparisons with Bonferroni correction, PϽ0.01 was considered significant.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Patient Population
Patient characteristics are summarized in the Table. Eighteen patients, 15 men and 3 women, were included in the biochemical analysis, and the average age of the patients was 54.9Ϯ8.7 years. Twelve of the patients were white, and 6 were black. Nine of the patients had an ischemic cardiomyopathy, 1 had a viral cardiomyopathy, and the remaining 8 had idiopathic dilated cardiomyopathies. The mean duration of LVAD support was 78.5Ϯ55.3 days (range 9 to 190 days). The majority of patients were supported with a HeartMate XVE (nϭ10). Five patients had a Thoratec LVAD, whereas 1 patient each had a HeartMate II, Thoratec BIVAD, or Abiomed BIVAD. The average pre-LVAD ejection fraction was 20%. When available, the post-LVAD/pretransplant ejection fraction was typically unchanged, although the duration of the time of the study after LVAD implantation varied considerably. The average age of the 4 patients in the isolated myocyte study was 50 years. All patients were male, 3 were white, and 1 was black. Three were supported by a HeartMate XVE LVAD for durations of 8, 51, and 279 days, respectively, and 1 patient did not have an LVAD. The average ejection fraction was 17.5%, and no patients had a post-LVAD ejection fraction available. The majority of patients were given some form of inotropic and/or vasopressor support at the time of LVAD implantation (Table) .
Load-Dependent Trafficking of ␤ARs in End-Stage Human Heart Failure
Previous studies have shown that mechanical unloading of the failing human heart ameliorates ␤AR abnormalities and improves cardiac dysfunction 5, 6 ; however, the mechanism responsible for this beneficial effect is currently unknown. To test whether endosomal sequestration of ␤ARs might play a role in regulating adrenergic responsiveness in the failing human heart, we fractionated by ultracentrifugation the plasma membrane and early and late endosomal compartments from human heart samples before and after implantation of an LVAD. Control heart samples from unmatched nonfailing human hearts were obtained from organ donors whose hearts were unsuitable for transplantation and who had no prior history of cardiac disease.
Human heart failure (HF) was characterized by marked downregulation of ␤ARs from the plasma membrane ( Figure  1A ; PϽ0.01 versus corresponding controls), as expected. 12, 13 Interestingly, the downregulation of ␤ARs at the plasma membrane was associated with a marked increase in the levels of the receptor in the early and late endosomal fractions compared with control hearts ( Figure 1A ; PϽ0.01 versus corresponding control hearts). Consistent with previous studies, 6, 19 mechanical unloading of the left ventricle through an LVAD significantly increased plasma membrane levels of ␤ARs ( Figure 1A) . Importantly, replenishment of plasma membrane ␤ARs after LVAD appeared to be associated with a marked reduction of "sequestered" endosomal pools of ␤ARs ( Figure 1A) , which suggests a redistribution of the receptors from the endosomal fractions to the plasma membrane. This replenishment of the receptors in the plasma membrane after LVAD appeared to restore ␤AR densities to control patient levels ( Figure 1A) .
Despite the marked differences in the intracellular distribution of ␤ARs among the different groups ( Figure 1A) , total ␤AR levels (after addition of all the fractions) were not statistically different in control and HF samples. Furthermore, the total number of receptors was not affected by mechanical unloading of the failing ventricle ( Figure 1B) . To test whether unloading of the heart after LVAD results in transcriptional modulation of ␤ 1 ARs or ␤ 2 ARs, resulting in replenishment of receptor at the plasma membrane, we performed Northern blot analysis. RNA was isolated from control, HF, and HF/LVAD patient samples, and the blots were probed with radiolabeled ␤ 1 AR or ␤ 2 AR probes. Significant transcriptional downregulation of ␤ 1 ARs was observed in HF and HF/LVAD samples compared with control samples ( Figure  1C ), which indicates that mechanical unloading by LVAD implantation does not modulate ␤ 1 AR transcription. Interestingly, we did not observe significant differences in the ␤ 2 AR transcript among the samples. Equal loading of RNA for each of the samples was confirmed by methylene blue staining of ribosomal RNA 28S and 16S on the nylon membrane after the transfer of RNA to the membrane ( Figure 1C ). To test whether increased ␤AR levels at the plasma membrane after LVAD would translate into restoration of ␤AR signaling, we measured adenylyl cyclase activity in plasma membrane fractions derived from hearts belonging to the different groups. As expected, HF samples displayed reduced basal and isoproterenol-stimulated adenylyl cyclase activity compared with normal hearts (Figure 1D ; PϽ0.01 versus control isoproterenol stimulation). Interestingly, LVAD support restored ␤AR/Gs protein coupling, as measured by a significant improvement in basal and isoproterenol-stimulated adenylyl cyclase activity in HF/ LVAD human hearts ( Figure 1D ; PϽ0.01 versus basal levels). Furthermore, direct activation of G protein by sodium fluoride showed significant reduction in adenylyl cyclase activity (data not shown) consistent with upregulation in the inhibitory G protein, G␣ i . 20 Taken together, these results suggest that ␤AR downregulation in human heart failure results from a combination of reduced receptor synthesis and enhanced intracellular receptor sequestration in various endosomal compartments and that ␤AR sequestration is a dynamic process that can be reversed by mechanical unloading of the failing human heart.
Load-Dependent Increase in ␤AR-Targeted PI3K Activity in Failing Human Hearts
Agonist-dependent sequestration of ␤ARs requires translocation and activation of ␤ARK1 by liberated G␤␥-subunits. 9 Therefore, we measured ␤ARK1 protein levels in myocardial lysates from the different patient groups. A marked increase in ␤ARK1 levels was seen in HF hearts compared with unmatched controls, which is consistent with previous studies (Figure 2A ). Importantly, a complete reversal of ␤ARK1 protein levels occurred in hearts after LVAD support ( Figure  2A) . We have previously shown that ␤ARK1 associates with PI3K to form a stable cytosolic complex that is recruited to the activated ␤ARs after receptor stimulation. 15 Furthermore, enhanced membrane-targeted ␤ARK1-associated PI3K activity is invariably associated with ␤AR dysfunction in different animal models of heart failure. 17, 20 To test whether an increase in ␤ARK1-associated PI3K activity occurs in human heart failure, ␤ARK1 was immunoprecipitated from the cardiac plasma membranes, and associated PI3K activity was measured. A marked increase in ␤ARK1-associated PI3K activity was seen in cardiac membranes before LVAD (Figure 2B) . Importantly, mechanical unloading resulted in a dramatic reduction of ␤ARK1-associated PI3K activity to levels similar to the controls ( Figure 2B ).
Selective Increase of PI3K␥ Activity in End-Stage Human Heart Failure
␤ARK1-associated PI3K activity is enhanced in human heart failure, and because ␤ARK1 can interact with either PI3K ␥or ␣-isoforms, we attempted to identify the PI3K isoform that contributes to the increase in PI3K activity. PI3K ␥and PI3K ␣-isoforms were immunoprecipitated from the myocardial lysates, and lipid kinase activity was measured in the immunoprecipitates. PI3K␥ activity was increased significantly in HF hearts, which showed that the PI3K ␥-isoform was responsible for the significant changes in ␤ARK1-associated PI3K activity ( Figure 3A and 3B) . Importantly, mechanical unloading after LVAD support resulted in a significant reduction of PI3K␥ activity ( Figure 3A and 3B) . In contrast, no appreciable change in PI3K␣ activity was seen in human heart failure samples compared with control ( Figure 3C and 3D), which suggests that PI3K␣ may not play a key role in end-stage heart failure. Taken together, these data demonstrate that the ␤AR abnormalities seen in human heart failure are associated with a significant increase in ␤ARK1- associated PI3K activity, with a selective increase in the activity of the PI3K ␥-isoform.
Overexpression of PIK Domain Peptide Restores Cardiac Contractility in Myocytes Isolated From Failing Human Hearts
Since failing human hearts displayed increased ␤ARK1associated PI3K activity and profound ␤AR abnormalities, we tested whether targeted inhibition of PI3K at the receptor might reconstitute ␤AR responsiveness in failing human cardiomyocytes. To this end, we infected failing cardiomyocytes with recombinant adenoviruses containing a FLAGtagged PIK domain of PI3K. 17 Human cardiac myocytes were infected at an MOI of 100 to result in significant expression of PIK domain peptide (AdPIK). Myocytes were also infected with adenoviruses encoding only GFP (AdGFP) or empty vector (AdEV) as controls. To test expression of the PIK domain peptide, we performed confocal microscopy on infected cardiomyocytes. The myocytes infected with empty vector (AdEV) showed minimal staining with Texas Red (Figure 4A ). In contrast, intense Texas Red staining was seen in cardiomyocytes on AdPIK infection, which showed expression of PIK domain peptide (AdPIK; Figure 4A ). Myocytes infected with only AdGFP showed strong GFP immunofluorescence ( Figure 4A) .
To test whether PIK overexpression could rapidly reconstitute ␤AR responsiveness to agonist in failing cardiomyocytes, contractility studies were performed on cells isolated from failing human hearts at the time of cardiac transplantation. The isolated cardiac myocytes were infected with either empty virus AdEV (HF-AdEV) or AdPIK (HF-AdPIK), and contractility studies were performed on uninfected (HF) or infected (36 to 48 hours after infection) cardiomyocytes. In multiple sets of cells, we measured basal and isoproterenolstimulated percentage of cell shortening, velocity of shortening (dL/dtϪ), and velocity of relaxation (dL/dtϩ). PIK overexpression markedly normalized the rate of cell contraction and relaxation under basal conditions and after stimula-tion with isoproterenol ( Figure 4B ; PϽ0.001 for isoproterenol versus basal levels, PϽ0.005 AdPIK isoproterenol versus HF isoproterenol and AdEV isoproterenol, ANOVA with Bonferroni correction). In addition, human cardiomyocytes infected with AdPIK displayed improved cellular contractility compared with AdEV or HF, both under basal conditions and on agonist stimulation ( Figure 4C ; PϽ0.001 for all isoproterenol versus basal, PϽ0.005 AdPIK isoproterenol versus HF isoproterenol and AdEV isoproterenol, ANOVA with Bonferroni correction). Taken together, these studies demonstrate that disruption of the ␤ARK1/PI3K complex improves failing myocyte function by reversing already established abnormalities in ␤AR function.
Discussion
The failing human heart is characterized by significant downregulation of ␤ARs at the plasma membrane and sequestration of receptors into stable intracellular pools, consistent with animal models of hypertrophy and heart failure. 17 In the present study, we demonstrate that mechanical unloading of the failing human heart depletes the stable intracellular reservoirs of ␤ARs, potentially promoting redistribution of the receptors to the plasma membrane. The concept of redistribution of receptors is consistent with restoration of ␤AR responsiveness after LVAD support, because we showed that no change in the ␤ 1 AR or ␤ 2 AR transcript levels occurred after mechanical unloading. Furthermore, mechanical unloading is associated with significant reduction in PI3K␥ activity and ␤ARK1-associated PI3K activity that is markedly elevated in failing human hearts. Importantly, competitive displacement of active PI3K from the ␤ARK1 complex by the PIK domain peptide of PI3K results in remarkable reversal of established ␤AR abnormalities in failing cardiomyocytes. These studies highlight a novel regulatory mechanism of ␤AR trafficking in conditions of heart failure that could potentially be regulated by PI3K activity.
␤ARs are the interface between the heart and the continuously changing environment. 10 Sudden cardiac overload rapidly induces ␤AR desensitization and downregulation, 3 and these abnormalities are believed to be intrinsically linked to the deleterious progression of cardiac dysfunction. 3, 10 According to the current paradigm, ␤AR internalization/ degradation along with a significant dampening of ␤AR transcription determines the downregulation of the ␤AR system in failing human hearts. 13, 21 In contrast to the current paradigm, the present studies show that end-stage failing human hearts are characterized by large intracellular pools of ␤ARs within endosomal compartments, consistent with animal models of heart failure. 17 Furthermore, we show that the change in the environmental conditions (ie, change in cardiac load or neurohumoral stimulation) might indeed promote the reverse trafficking of "sequestered" ␤ARs back to normal function at the plasma membrane, because normalized receptor numbers are not mirrored by transcriptional activation. This is an important concept and a shift from the current understanding wherein it is thought that receptors targeted for degradation are trafficked to the late endosomes. 11 Although it is not known how long ␤ARs reside within the late endosomal compartment before degradation, the reduction of receptor densities from the late endosomal component of failing human hearts on mechanical unloading supports the concept of reverse trafficking. It is proposed that mechanical unloading of the heart by an LVAD appears to initiate a process of reverse remodeling 22 that is associated with significant recovery of ␤AR myocardial responsiveness and ␤AR densities and reversal of ryanodine receptor hyperphosphorylation. 6, 19, 23, 24 This reverse remodeling in response to LVAD therapy supports the contention that the failing human heart retains some capacity for recovery. Furthermore, because the downregulation of ␤ARs is reversible, it suggests that reverse trafficking of receptors could be integral to the remodeling process.
Evidence from previous studies has demonstrated that LVAD support results in significant improvement in ␤AR responsiveness and restoration of the inotropic response to sympathetic stimulation. 6 It has been shown that the amelioration of cardiac function after LVAD support is associated with recovery in receptor density at the cardiac membrane, 19 consistent with the present studies. Importantly, the present studies demonstrate that the recovery of receptor density at the plasma membrane after LVAD could be due to redistribution of the sequestered ␤ARs from various endosomal compartments to the plasma membrane. This concept is supported by the RNA analysis, which showed no significant changes at the transcriptional level in the paired samples after mechanical unloading by LVAD. The lack of change in total ␤AR densities among nonfailing and failing human hearts suggests that ␤AR endosomal sequestration might be an important mechanism governing the process of receptor downregulation from the cell.
The mechanisms by which mechanical unloading of the left ventricle might promote the translocation of ␤ARs toward the plasma membrane are still unknown. Besides reducing mechanical stress, LVAD support has been shown to decrease adrenergic hyperactivation and the local release of cytokines that might be involved in the regulation of cardiac function, 25, 26 and therefore, it might exert beneficial effects on ␤AR signaling either directly or indirectly. The partial recovery of ventricular function by reverse remodeling after LVAD could likely involve regulation of multiple signaling pathways, 22 and we believe that the dynamic regulation of PI3K␥ activity seen in the present studies would be integral to this process.
The present study shows that end-stage failing human hearts are characterized by selective augmentation of PI3K␥ activity, and these data are indeed consistent with our previous observations in animal models of hypertrophy and failure. 17 Surprisingly, PI3K␥ activation can be completely reversed by mechanical unloading of the failing ventricle. In contrast, we did not observe any significant changes in PI3K␣ activity among the groups. These results from end-stage failing human hearts are consistent with recent studies in mice that showed significant activation of PI3K␣ on physical training 3 or PI3K␥ activation in response to pathological stresses. 3 Activation of PI3K␥ is thought to be involved in deleterious signaling, because overexpression of catalytically inactive PI3K␥ results in amelioration of cardiac function in mouse models of heart failure. 20, 27 The reversal in the activation of PI3K␥ after LVAD suggests that this enzyme might be integral to the beneficial reverse remodeling that occurs after mechanical unloading of the failing ventricle. Indeed, PI3K regulates multiple signaling pathways, including Akt/GSK and p70S6K, and dynamic regulation of AKT, p70S6K, and mitogen-activated protein kinase/extracellular signal-regulated kinase is seen before and after LVAD implantation, 28 which suggests that targeting PI3K␥ could be a potential therapeutic strategy in conditions of heart failure.
It is known that ␤ARK1 interacts with PI3K to form a cytosolic complex and mediates PI3K recruitment to the agonist-activated ␤AR. 15 Furthermore, ␤ARK1-mediated PI3K activity at the receptor complex plays a critical role in receptor downregulation (internalization) in mice. 20 The present studies in the human heart show that a significant increase in ␤ARK1-associated PI3K activity occurs in cardiac membranes from failing left ventricles, which suggests a critical role for the ␤ARK1/PI3K complex in the process of receptor downregulation seen in heart failure. Displacement of active PI3K from the ␤ARK/PI3K complex by a dominant-negative strategy results in inhibition of receptor internalization and significant amelioration of cardiac dysfunction in animal models of heart failure. 20, 27 Therefore, the displacement of active PI3K from the ␤ARK/PI3K complex would be an attractive strategy for novel therapeutic interventions in heart failure. Consistent with this idea, our in vitro gene therapy approach indicates that the competitive displacement of PI3K from ␤ARK1 markedly improves multiple parameters of contractility in failing human cardiomyocytes. One of the potential mechanisms by which the PIK domain peptide could provide these beneficial effects may involve changing the fate of agonist-stimulated ␤ARs and redirecting sequestered pools of ␤ARs toward plasma membrane, which would result in functional receptors and enhanced contractility. Because of the limited amount of available primary human cardiomyocytes, we were not able to perform molecular/ biochemical analyses to address ␤AR compartmentalization after PI3K inhibition in human cardiac cells.
On the basis of our observations, we believe that inhibition of PI3K by a dominant-negative approach could be a novel therapeutic strategy. This approach is critically different from the strategy of using the inhibitor of ␤ARK1, ␤ARKct (the carboxyl-terminus of ␤ARK1), which has been shown to ameliorate contractility of failing human cardiomyocytes. 18, 29 ␤ARKct sequesters G␤␥-subunits, which leads to inhibition of receptor phosphorylation by ␤ARK1, and this results in the amelioration of cardiac function. 18 The activation and subsequent reversal of ␤ARK1associated PI3K activity after mechanical unloading reflects the fact that ␤ARK1-associated PI3K activity is part of the deleterious signal activated in conditions of heart failure that is reversed as part of the beneficial remodeling that occurs after LVAD support. The reduction in ␤ARK1-associated PI3K activity could be due to lower PI3K␥ activity or reduced levels of ␤ARK1. Dynamic regulation of ␤ARK1 protein levels before and after LVAD is consistent with previous studies 18, 29 and may be one of the key components in the formation of the ␤ARK1/PI3K complex and initiation of deleterious signaling.
In conclusion, the present studies demonstrate that endstage failing human hearts are characterized by a significant increase in ␤ARK1-associated PI3K activity. The augmentation of ␤ARK1-associated PI3K activity is specifically due to the increase in PI3K␥ isoform activity. Mechanical unloading of the heart by an LVAD reduces ␤ARK1-associated PI3K activity and results in restoration of plasma membrane ␤AR densities to densities similar to those of the nonfailing heart. The restoration of plasma membrane ␤AR densities potentially could occur by redistribution of the receptors from the sequestered endosomal compartments. Finally, a dominantnegative strategy to inhibit the recruitment of active PI3K to the ␤AR complex improves multiple parameters of contractility in failing human cardiomyocytes, which suggests that targeting the ␤ARK1/PI3K complex could be a novel, attractive therapeutic strategy to normalize ␤AR function in human heart failure.
